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Background: Clinical studies have suggested an association between bisphosphonate use and the onset of atrial fibrillation. However, data on the 
risk of developing atrial fibrillation, stroke and cardiovascular mortality with use of bisphosphonate is conflicting.
objective: To evaluate the risk of serious atrial fibrillation (AF events that required hospital admission), stroke and cardiovascular mortality with 
use of bisphosphonates through a systematic review of the literature.
methods: We searched the Pub Med, CENTRAL and EMBASE databases for observational studies and randomized controlled trials (RCT) on 
the use of bisphosphonates from 1966 to April 2012 that reported the number of patients who developed serious atrial fibrillation, stroke and 
cardiovascular mortality at follow up. The random effects Mantel-Haenszel test was used to evaluate relative risk adverse cardiovascular outcomes 
with use of bisphosphonates.
results: Six observational studies (N=149,856) and six RCTs (N=41, 375) were included for analysis. On pooling observational studies, there 
was an increased risk of atrial fibrillation (OR 1.27 95% CI 1.16-1.39) among bisphosphonate users. Further, analysis of RCTs revealed statistically 
significant increase in risk of serious atrial fibrillation (OR 1.40 95%CI 1.02-1.93) and no increase in risk of stroke (OR 1.07 95%CI 0.85-1.34) and 
cardiovascular mortality (OR 0.92 95%CI 0.68-1.26) with use of bisphosphonates.
conclusion: Evidence from RCTs and observational studies suggests significantly increased risk of serious atrial fibrillation, but no increase in risk 
of stroke or cardiovascular mortality with use of bisphosphonates. Additional prospective studies are required to further investigate and assess this 
association.
